The post Inside Strategy and MSTR’s index exclusion risk and what that means for Bitcoin appeared on BitcoinEthereumNews.com. Key Takeaways Why is MSTR suddenly facing real exclusion risk? MSCI’s updated rules target companies whose balance sheets are dominated by Bitcoin, putting MSTR directly in the danger zone. How big could the impact be if MSTR is removed? JPMorgan estimates $2.8 billion in forced passive outflows from MSCI alone. And, up to $8.8 billion+ if other index providers follow. The Treasury market is waking up to a reality check. Volatility has spiked since Q4 kicked off, and investors are noticing their algorithms aren’t holding up, leaving many stakeholders deep underwater. Strategy [MSTR] hasn’t escaped the pain either. After back-to-back down quarters, the stock is down nearly 70% to $177, back to Q4 2024 levels, while Bitcoin [BTC] only lost about 21% in the same stretch. JP Morgan analysts are now flagging a potential risk –  MSTR could be excluded from the upcoming Morgan Stanley Capital International (MSCI) review in January. The question is, is this a classic “sell-the-news” event? MSTR’s valuation loop falters at the worst possible time MSTR’s underlying engine is starting to show cracks.  From a technical standpoint, MSTR has lost 40% in just the last month and is down 68% from its ATH. The company currently holds 649,870 Bitcoin at an average cost of $74,433 per coin – A massive exposure. Technically, that means if BTC drops another 8% off the $80k-level, the company’s position would move fully into the red. That pressure has hit the stock and its premium hard, making $160 a solid floor for MSTR. Source: TradingView (MSTR/USDT) Notably, this is exactly why JP Morgan’s thesis matters.  MicroStrategy’s old playbook was simple – Raise money from the stock, buy BTC, the stock goes up, and repeat. However, that loop is now broken. When the stock trades near its BTC value, there’s no premium… The post Inside Strategy and MSTR’s index exclusion risk and what that means for Bitcoin appeared on BitcoinEthereumNews.com. Key Takeaways Why is MSTR suddenly facing real exclusion risk? MSCI’s updated rules target companies whose balance sheets are dominated by Bitcoin, putting MSTR directly in the danger zone. How big could the impact be if MSTR is removed? JPMorgan estimates $2.8 billion in forced passive outflows from MSCI alone. And, up to $8.8 billion+ if other index providers follow. The Treasury market is waking up to a reality check. Volatility has spiked since Q4 kicked off, and investors are noticing their algorithms aren’t holding up, leaving many stakeholders deep underwater. Strategy [MSTR] hasn’t escaped the pain either. After back-to-back down quarters, the stock is down nearly 70% to $177, back to Q4 2024 levels, while Bitcoin [BTC] only lost about 21% in the same stretch. JP Morgan analysts are now flagging a potential risk –  MSTR could be excluded from the upcoming Morgan Stanley Capital International (MSCI) review in January. The question is, is this a classic “sell-the-news” event? MSTR’s valuation loop falters at the worst possible time MSTR’s underlying engine is starting to show cracks.  From a technical standpoint, MSTR has lost 40% in just the last month and is down 68% from its ATH. The company currently holds 649,870 Bitcoin at an average cost of $74,433 per coin – A massive exposure. Technically, that means if BTC drops another 8% off the $80k-level, the company’s position would move fully into the red. That pressure has hit the stock and its premium hard, making $160 a solid floor for MSTR. Source: TradingView (MSTR/USDT) Notably, this is exactly why JP Morgan’s thesis matters.  MicroStrategy’s old playbook was simple – Raise money from the stock, buy BTC, the stock goes up, and repeat. However, that loop is now broken. When the stock trades near its BTC value, there’s no premium…

Inside Strategy and MSTR’s index exclusion risk and what that means for Bitcoin

Key Takeaways

Why is MSTR suddenly facing real exclusion risk?

MSCI’s updated rules target companies whose balance sheets are dominated by Bitcoin, putting MSTR directly in the danger zone.

How big could the impact be if MSTR is removed?

JPMorgan estimates $2.8 billion in forced passive outflows from MSCI alone. And, up to $8.8 billion+ if other index providers follow.


The Treasury market is waking up to a reality check. Volatility has spiked since Q4 kicked off, and investors are noticing their algorithms aren’t holding up, leaving many stakeholders deep underwater.

Strategy [MSTR] hasn’t escaped the pain either. After back-to-back down quarters, the stock is down nearly 70% to $177, back to Q4 2024 levels, while Bitcoin [BTC] only lost about 21% in the same stretch.

JP Morgan analysts are now flagging a potential risk –  MSTR could be excluded from the upcoming Morgan Stanley Capital International (MSCI) review in January. The question is, is this a classic “sell-the-news” event?

MSTR’s valuation loop falters at the worst possible time

MSTR’s underlying engine is starting to show cracks. 

From a technical standpoint, MSTR has lost 40% in just the last month and is down 68% from its ATH. The company currently holds 649,870 Bitcoin at an average cost of $74,433 per coin – A massive exposure.

Technically, that means if BTC drops another 8% off the $80k-level, the company’s position would move fully into the red. That pressure has hit the stock and its premium hard, making $160 a solid floor for MSTR.

Source: TradingView (MSTR/USDT)

Notably, this is exactly why JP Morgan’s thesis matters. 

MicroStrategy’s old playbook was simple – Raise money from the stock, buy BTC, the stock goes up, and repeat. However, that loop is now broken. When the stock trades near its BTC value, there’s no premium left to fund buying.

For example, if MSTR’s BTC/share is worth $150 and the stock trades at $300, the company can sell shares and buy BTC. However, if the stock is trading closer to $150, there’s no premium left. So, the cycle stops.

With that in mind, MSTR’s possible exclusion from MSCI doesn’t feel hypothetical anymore. And, with the decision less than two months away, what exactly are analysts expecting from this high-risk event?

Massive outflows loom as Microstrategy faces index risk

MSCI’s new criteria for DATs puts MSTR directly in the spotlight. 

MSCI has indicated that firms whose Bitcoin holdings dominate their balance sheets could be re-classified. In a more severe scenario, they could even be removed from major indices altogether.

And, the market is already pricing that in. As mentioned above, MSTR’s valuation premium has been shrinking fast. That’s only added to investor concerns, keeping the stock at risk of sliding down towards the $160-level.

Source: X (Matthew Sigel)

The bigger issue? Bloomberg reported that JPMorgan estimates $2.8 billion in passive flows would be forced to sell if MSCI removes MSTR. And, if other indexes mirror this move, the total outflows could climb to $8.8 billion+.

In short, MSTR is at a real inflection point. 

The company is still adding BTC using debt. However, in a risk-off market that strategy is starting to look increasingly exposed. That’s why a full MSCI exclusion in January is no longer just a headline. Instead, it’s a legitimate risk on the table.

Previous: Tensor (TNSR) crypto up by 445% as crypto market bleeds, but will it last?
Next: Bitcoin – THIS metric could save ‘weak’ market structure after BTC hits $85K!

Source: https://ambcrypto.com/inside-strategy-and-mstrs-index-exclusion-risk-and-what-that-means-for-bitcoin/

Market Opportunity
Index Cooperative Logo
Index Cooperative Price(INDEX)
$0.5336
$0.5336$0.5336
+5.20%
USD
Index Cooperative (INDEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26